Skip to content

Study · Observational study · n = 23 · 2026

4 results

Comparison of lifestyle, surgery, and semaglutide for weight management in endometrial cancer: a prospective observational study.

Wei Y, Gong Y, Gong J, Zeng H, Zhong Z, Xiong Y, Li X

Journal of obstetrics and gynaecology : the journal of the Institute of Obstetrics and Gynaecology24 Jul 2026

PMID42495930 (opens in a new tab)DOI10.1080/01443615.2026.2701996 (opens in a new tab)PepBankPUB-42495930
Publisher pagePubMedAsk about this study
Jump to 4 results

Summary

BackgroundTo compare sleeve gastrectomy, semaglutide therapy, and the Diet, Exercise, Accompany and Refresh (DEAR) weight management programme for weight control, metabolic improvement, and oncological outcomes in patients with endometrial cancer receiving fertility-sparing treatment.MethodsIn this prospective observational study, 53 patients received sleeve gastrectomy (n = 10), semaglutide therapy (n = 23), or the DEAR programme (n = 20) after multidisciplinary assessment and shared decision-making. Anthropometric and metabolic measures and tumour response were assessed over two years.ResultsAt 1 year, all groups lost weight; the sleeve gastrectomy group had the largest body mass index reduction compared with the semaglutide group (difference = 4.04 kg/m2, p < 0.05) and the DEAR group (difference = 2.12 kg/m2, p < 0.05). By 2 years, weight regain was less frequent in the DEAR group (14.3%) than in the semaglutide (55.6%) and sleeve gastrectomy (66.7%) groups (p = 0.037). The DEAR group showed more stable metabolic improvements and the highest complete tumour remission rate (85.0%), followed by the semaglutide group (73.9%) and the sleeve gastrectomy group (60.0%).ConclusionSleeve gastrectomy produced rapid short-term weight loss, whereas the DEAR programme showed better medium-term weight maintenance, metabolic stability, and tumour response. Integrated lifestyle support may be a useful medium-term strategy for patients seeking fertility preservation.
CC BYText from Europe PMC. Highlighted sentences are the source of results.

Results from this study4

4 results from studies that gave the peptide. 4 results from people.

  1. 01HumanObservational studyEfficacy outcome

    In patients with endometrial cancer receiving fertility-sparing treatment, the semaglutide group lost weight at 1 year.

    In plain wordsIn women with endometrial cancer, those who took semaglutide lost weight at 1 year.

    Peptide
    Semaglutide
    Outcome
    DecreaseWeight loss at 1 year
    Study

    n = 23

    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    Dose not stated · 1 yearAs given in this study (human).

    Source sentences

    Summary
    At 1 year, all groups lost weight
    2 context sentences
    Summary · context
    In this prospective observational study, 53 patients received sleeve gastrectomy (n = 10), semaglutide therapy (n = 23), or the DEAR programme (n = 20) after multidisciplinary assessment and shared decision-making.
    Summary · context
    Anthropometric and metabolic measures and tumour response were assessed over two years.
  2. 02HumanObservational studyEfficacy outcome

    In patients with endometrial cancer receiving fertility-sparing treatment, complete tumour remission occurred in 73.9% of the semaglutide group.

    In plain wordsIn women with endometrial cancer, the tumour went into complete remission in 73.9% of those who took semaglutide.

    Peptide
    Semaglutide
    Outcome
    Not applicableComplete tumour remission rate
    Study

    n = 23

    Outcome group
    Tumor growth · Cancer
    Studied dose
    Dose not stated · 2 yearsAs given in this study (human).

    Measurements

    Complete tumour remission rate
    73.9%
    semaglutide group

    Source sentences

    Summary
    The DEAR group showed more stable metabolic improvements and the highest complete tumour remission rate (85.0%), followed by the semaglutide group (73.9%) and the sleeve gastrectomy group (60.0%).
    2 context sentences
    Summary · context
    In this prospective observational study, 53 patients received sleeve gastrectomy (n = 10), semaglutide therapy (n = 23), or the DEAR programme (n = 20) after multidisciplinary assessment and shared decision-making.
    Summary · context
    Anthropometric and metabolic measures and tumour response were assessed over two years.
  3. 03HumanObservational studyEfficacy outcome

    In patients with endometrial cancer, the BMI reduction at 1 year was smaller with semaglutide than with sleeve gastrectomy (difference 4.04 kg/m2).

    In plain wordsIn women with endometrial cancer, semaglutide lowered body mass index less than sleeve gastrectomy surgery did at 1 year.

    Peptide
    Semaglutide
    Outcome
    DecreaseBMI reduction at 1 year versus sleeve gastrectomy
    Study

    n: not reported in source

    Comparator
    Sleeve gastrectomy
    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    Dose not stated · 1 yearAs given in this study (human).

    Measurements

    BMI reduction difference versus sleeve gastrectomy
    4.04 kg/m2
    semaglutide group

    Source sentences

    Summary
    the sleeve gastrectomy group had the largest body mass index reduction compared with the semaglutide group (difference = 4.04 kg/m2, p < 0.05)
    2 context sentences
    Summary · context
    In this prospective observational study, 53 patients received sleeve gastrectomy (n = 10), semaglutide therapy (n = 23), or the DEAR programme (n = 20) after multidisciplinary assessment and shared decision-making.
    Summary · context
    Anthropometric and metabolic measures and tumour response were assessed over two years.
  4. 04HumanObservational studyEfficacy outcome

    In patients with endometrial cancer, weight regain by 2 years was more frequent with semaglutide (55.6%) than with the DEAR programme (14.3%).

    In plain wordsIn women with endometrial cancer, weight regain after 2 years was more common with semaglutide than with the DEAR lifestyle programme.

    Peptide
    Semaglutide
    Outcome
    IncreaseWeight regain by 2 years
    Study

    n: not reported in source

    Comparator
    DEAR programme
    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    Dose not stated · 2 yearsAs given in this study (human).

    Measurements

    Weight regain
    55.6%
    semaglutide group

    Source sentences

    Summary
    By 2 years, weight regain was less frequent in the DEAR group (14.3%) than in the semaglutide (55.6%) and sleeve gastrectomy (66.7%) groups (p = 0.037).
    2 context sentences
    Summary · context
    In this prospective observational study, 53 patients received sleeve gastrectomy (n = 10), semaglutide therapy (n = 23), or the DEAR programme (n = 20) after multidisciplinary assessment and shared decision-making.
    Summary · context
    Anthropometric and metabolic measures and tumour response were assessed over two years.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    11 Oct 2026, 00:04 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:06 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.